Season 1, Episode 3

Cracking the code: Navigating the Ever-Changing Biotech Landscape

Sep 13, 2023 | Podcast, Season 1 | 0 comments

Sabine Hutchison sits down with the accomplished Dr. Allison Jeynes-Ellis, a visionary leader whose journey spans medicine, oncology, and the life sciences.  

Join Seuss+ CEO and Co-Founder Sabine Hutchison as she sits down with the accomplished Dr. Allison Jeynes-Ellis, a visionary leader whose journey spans medicine, oncology, and the life sciences.  

With over three decades of experience, Allison has held key positions in esteemed institutions and collaborated with pharmaceutical giants like Roche, AstraZeneca, and J&J. 

In this episode, they delve into Allison’s remarkable journey, from practicing medicine to assuming the role of CEO at Avillion LLP. Renowned for its innovative life sciences investment approach, Avillion co-develops and finances late-stage pharmaceutical projects. Allison’s insights, cultivated through her extensive career, provide a unique perspective on the industry’s challenges and opportunities.  

Dr. Allison Jeynes-Ellis – Bio  

 After qualifying as an MD, Dr Allison Jeynes-Ellis spent time practicing medicine and specialising in oncology working at various NHS institutions, including The Royal Marsden, London before moving into the life sciences industry predominantly within research and development. Now with over 30 years’ experience she has led the strategic direction of Avillion LLP as its CEO since 2014 and has a proven track record of delivering results.  

Avillion LLP is a boutique Life Sciences investment firm who fund and operationalise clinical trials for other companies. Avillion historically has invested in post POC Co-Development deals from $50m to $250m taking all the clinical & regulatory risk around approval but is currently evolving into early phases of development and consulting.  

Prior to Avillion, Allison held a range of senior roles, including Medical Director for Wyeth for 6 years and International Project Team Leader for many compounds in development, leading global Phase III programmes through to successful US and EU filings.  

Allison sits on the Board of Directors of Agenus and Anaveon and is the Non-Executive Chair of Oxsonics. Allison is also a Senior Advisor to Blackstone Life Sciences.

Join the discussion and listen to the full episode here.

Related Episodes

Episode 1 Smart KPIs for Biotechs

Season 1, Episode 1 Smart KPIs for BiotechsSabine Hutchison and Alan Morgan discuss the importance of measuring what truly matters in clinical trials and the significance of smart Key Performance Indicators (KPIs) for Biotech companies.Seuss+ CEO and Co-Founder Sabine...


Submit a Comment

Your email address will not be published. Required fields are marked *

Stay Connected to Get The Latest Podcast Alerts


Listen Now!

An informative podcast series designed quite literally cut the unnecessary talk and get straight to the point and heart of many life science and Biotech conversations that need to happen for our industry to evolve, innovate and get smarter—faster.

Now Live!

Now Live!

Now Live!